Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia.
OBJECTIVE
To investigate the effects of oral oxybutynin chloride (OC) on standard urodynamic measures in children with myelomeningocele (MMC) and detrusor hyperreflexia.


METHODS
Forty-one MMC children with detrusor hyperreflexia (19 boys and 22 girls, aged 2 months to 15 years; mean 4.9 years) were evaluated urodynamically before and within 3 months after initiation of oral OC therapy (0.2 to 0.3 mg/kg/day). Therapy with oral OC was always combined with clean intermittent catheterization (CIC).


RESULTS
Oral OC treatment caused an increase in bladder capacity from 141 +/- 96 to 197 +/- 99 mL (+ 40%; P < 0.01), a decrease in detrusor pressure at maximal capacity from 45 +/- 32 to 28 +/- 23 cm H2O (-38%; P < 0.01), and an increase in detrusor compliance from 6.5 +/- 5.6 to 16.8 +/- 13.7 mL/cm H2O (+ 158%; P < 0.01). Improvement in urodynamic measures and continence were correlated. After a follow-up of at least 2 years, effective protection of renal function was achieved in 38 of the 41 children (93%) with conservative therapy alone. Adverse effects resulted in discontinuation of oral OC treatment in only 2 cases.


CONCLUSIONS
Treatment with oral OC and CIC is effective and safe in children with MMC and detrusor hyperreflexia and should be initiated early when indicated by urodynamic findings.
Goessl
C
C
Department of Urology, Benjamin Franklin Medical Center, Free University of Berlin, Germany.
Knispel
H H
HH
Fiedler
U
U
Härle
B
B
Steffen-Wilke
K
K
Miller
K
K
D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018680:Cholinergic Antagonists / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D008591:Meningomyelocele / Q000503:physiopathology*; D012021:Reflex, Abnormal / Q000187:drug effects*; D001743:Urinary Bladder / Q000187:drug effects* / Q000294:innervation / Q000503:physiopathology*; D014563:Urodynamics / Q000187:drug effects*
D018680:Cholinergic Antagonists; D008333:Mandelic Acids; C005419:oxybutynin